RxDoctor Payments Data

Lee Ming Shum, MD

Rheumatology · Mayaguez, PRNPI 1568741387

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 81.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $2,807 and has fallen 93.4% since, to $185 in 2025.

$7,052in general payments, 2019–2025

Across 69 payments — averaging $102.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • PBG Puerto Rico LLC$283
  • Amgen$264
  • E.r. Squibb & Sons, L.L.C.$256
  • GSK$151
  • Johnson & Johnson$143
  • plus $234 from 5 others

What the payments were for

  • Consulting fees$2,90041%
  • Speaking & faculty fees$2,43835%
  • Food & beverage$1,71424%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,052 in reported general payments places this provider in the 70th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$2,286
Medicare patients
12
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept434$3,247,749
Humira(Cf) PenAdalimumab336$2,336,370
Orencia ClickjectAbatacept203$1,160,214
RinvoqUpadacitinib134$864,107
Taltz AutoinjectorIxekizumab73$498,626
Actemra ActpenTocilizumab99$309,780
StelaraUstekinumab11$308,453
Xeljanz XrTofacitinib Citrate52$300,460
Cosentyx Sensoready PenSecukinumab19$284,653
OrenciaAbatacept36$205,094
ProliaDenosumab98$173,697
BenlystaBelimumab32$158,090
XeljanzTofacitinib Citrate24$137,423
SimponiGolimumab13$78,540
Teriparatide23$51,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$5,722$864,107134 claims
Johnson & JohnsonStelara, Simponi$143$386,99324 claims
E.r. Squibb & Sons, L.L.C.Orencia$256$205,09436 claims
AmgenProlia$264$173,69798 claims
GSKBenlysta$151$158,09032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →